Emerging literature suggests that metabolic pathways play an important role in the maintenance and progression of human cancers. In particular, recent studies have implicated lipid biosynthesis and desaturation as a requirement for tumor cell survival. In the studies reported here, we aimed to understand whether tumor cells require the activity of either human isoform of stearoyl-CoA-desaturase (SCD1 or SCD5) for survival.
Abstract
Emerging literature suggests that metabolic pathways play an important role in the maintenance and progression of human cancers. In particular, recent studies have implicated lipid biosynthesis and desaturation as a requirement for tumor cell survival. In the studies reported here, we aimed to understand whether tumor cells require the activity of either human isoform of stearoyl-CoA-desaturase (SCD1 or SCD5) for survival.
Inhibition of SCD1 by siRNA or a small molecule antagonist results in strong induction of apoptosis and growth inhibition when tumor cells are cultured in reduced (2%) serum conditions but has little impact on cells cultured in 10% serum. Depletion of SCD5 had minimal effects on cell growth or apoptosis. Consistent with the observed dependence on SCD1 but not SCD5, levels of SCD1 protein increased in response to decreasing serum levels. Both induction of SCD1 protein and sensitivity to growth inhibition by SCD1 inhibition could be reversed by supplementing growth media with unsaturated fatty acids, the product of the enzymatic reaction catalyzed by SCD1. Transcription profiling of cells treated with an SCD inhibitor revealed strong induction of markers of endoplasmic reticulum stress. Underscoring its importance in cancer, SCD1 protein was found to be highly expressed in a large percentage of human cancer specimens. SCD inhibition resulted in tumor growth delay in a human gastric cancer xenograft model. Altogether, these results suggest that desaturated fatty acids are required for tumor cell survival and that SCD may represent a viable target for the development of novel agents for cancer therapy.
Introduction
Stearoyl-CoA Desaturase (SCD) enzymes catalyze the conversion of saturated fatty acids (SFA) to Δ-9 monounsaturated fatty acids (MUFA). These enzymes preferentially convert stearic acid (C18:0) to oleic acid (C18:1), and palmitic acid (C16:0) to palmitoleic acid (C16:1) (1). In mammals, the most extensively studied SCDs are those from the mouse where four isoforms (SCD1-4) are known to exist (reviewed in (2) ). Of the two human SCD genes, SCD1 and SCD5, only human SCD1 has been extensively studied and is the nearest ortholog of the four murine enzymes. Much less is known about human SCD5, however it appears by sequence comparison to be divergent from the four rodent SCD isoforms (3) .
The products of SCD enzymes, oleic and palmitoleic acids are the most abundant monounsaturated fatty acids and represent important precursors for the formation of complex lipids including phospholipids, triglycerides, cholesterol esters, wax esters and diacylglycerols. Hence, the activity of SCD enzymes is likely to have wide ranging effects on cellular membrane physiology, energy storage and signaling as well as broad effects on animal physiology. Recently, a number of reports have implicated SCD1 expression and activity in the pathogenesis of cancer (for review see (4) ). Human SCD1 mRNA was found to be overexpressed in a variety of human cancers including colon, esophageal and hepatocellular carcinomas relative to the corresponding normal tissues (5). Additionally, SCD1 levels were found to be elevated in mice and rats that are genetically predisposed to develop certain cancers (6). SCD1 levels were also observed to be up-regulated in transformed cells. Both expression and activity of human SCD1 were found to increase in human fibroblasts upon transformation by SV40 (7); the same authors subsequently showed that reducing SCD1 levels in SV40 transformed fibroblasts using antisense mRNA expression resulted in reduced proliferation and a diminished capacity for anchorage-independent growth (8). Conversely, it was recently reported that SCD1 levels decreased in fibroblasts undergoing senescence compared to low passage, rapidly proliferating fibroblasts (9, 10).
As with engineered fibroblasts, human cancer cell lines have been reported to depend on the expression of SCD1 for proliferation and survival. Scaglia and Igal showed that even modest suppression of SCD1 levels and activity in A549 lung cancer cells by stable expression of SCD1 targeted antisense RNA resulted in reduced proliferation rate, a reduced capacity for growth in soft agar and delayed growth of xenografts in nude mice (10). The reduction in tumorigenic activity in these cell lines with reduced SCD1 activity correlated with reduced levels of monounsaturated fatty acids and has been linked to effects on the AKT and AMPK signaling pathways (10, 11). The studies reported here demonstrate for the first time that tumor cells are highly dependent on MUFA for proliferation and that in the absence of an exogenous MUFA source, they become entirely dependent on the activity of SCD1. Further we show that levels of SCD1 protein are tightly regulated by exogenous MUFA availability and that high expression of SCD1 correlates with the dependence of tumor cells upon its activity.
Finally, high SCD1 protein was commonly found in a variety of human cancers and pharmacologic inhibition of SCD1 in a high expressing xenograft resulted in significant antitumor effects. Together, these results strongly suggest that SCD1 represents a viable target for the development of novel anti-cancer agents.
Materials and Methods
Cell lines and culture conditions. A549, H1299 and FaDu human cancer cell lines were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained in Dulbecco's Modified Eagle's Medium containing high glucose and Lglutamine (DMEM, Invitrogen (Carlsbad, CA, USA)) supplemented with Fetal Bovine conjugated oleic acid (Catalog #O3008) and fatty acid free bovine serum albumin (BSA, Catalog #A8806) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
RNA interference.
Small, interfering RNA (siRNA) duplexes targeting human SCD1 (Catalog #J-005061-07, J-005061-08 and J-005061-10) and human SCD5 (Catalog #J-008416-06, J-008416-07 and J-008416-08) were obtained from Dharmacon RNAi Technologies (Lafayette, CO, USA). RISC-Free siRNA (Catalog #D-001220-01) and a custom synthesized siRNA designed against the firefly luciferase mRNA sequence (5'-GGGACGAAGACGAACACUUC-3') were used as negative controls. Cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. siRNAs were delivered to cells at a final concentration of 20nM.
Antibodies and Immunoblotting.
Antibodies specific for human SCD1 and human SCD5 were raised by immunizing rabbits with fusion proteins containing an SCD1 specific peptide sequence (PPSRVLQNGGDKLETMPLYLEDDIRPDIKDD) and an SCD5 specific peptide sequence (MPGPATDAGKIPFCDAKEEIRAGLESSEGG). To generate the fusion protein antigens, oligonucleotides encoding the SCD1 and SCD5 peptides were cloned into the pEX34a bacterial expression vector and fusion proteins were expressed in Escherichia coli K537 as described (15) . Specificity of the antisera was confirmed by testing against the full length proteins using immunoprecipitation and western blotting techniques. Mouse anti-actin antibody (catalog #MAB1501R) was purchased from 7 Chemicon (Bellarica, MA, USA). Labeled sheep anti-Rabbit IgG (catalog #611-632-122) was purchased from Rockland Immunochemicals (Gilbertsville, PA, USA).
Labeled goat anti-mouse IgG (catalog #A21057) was purchased from Invitrogen. Antip85 cleaved PARP polyclonal antibody (Catalog #G7341) was purchased from Promega (Madison, WI, USA). FITC-conjugated anti-rabbit antibody (Catalog #554020) was acquired from BD Biosciences (San Jose, CA, USA).
Following siRNA or compound treatments, cells were lysed by scraping into RIPA buffer (Sigma-Aldrich, catalog #R0278) containing Protease Inhibitor Cocktail (Sigma-Aldrich, catalog #P8340). Protein concentrations were determined and western blotting was performed using standard procedures. Blots were probed for 2 hours with the indicated primary antibodies and developed using infrared dye labeled secondary antibodies. Blot images were captured using a Li-Cor Odyssey Infrared Imaging System.
Quantitation of Apoptosis.
Induction of apoptosis was assessed by measuring the number of cells producing the p85 fragment of cleaved poly-ADP Ribose Polymerase (PARP) by Flow Cytometry as previously described (16) . Anti-p85 cleaved PARP polyclonal antibody was used at a 
SCD activity determination.
In vitro SCD1 activity was determined using a modified version of the assay described by Obukowicz et al. (17) . Microsomes were prepared from Sf9 insect cells coexpressing recombinant human SCD1 and Cytochrome b5/ b5R. Microsome mix, containing 1μg of baculovirus expressed human SCD1 in 100mM potassium phosphate buffer (pH 7.4), and compound in DMSO was added to each well and pre-incubated for 10 min. The reaction was initiated with the addition of the substrate mix which contained the following: 5μM Stearoyl-CoA (Sigma Aldrich), 0.25μM Stearoyl [9,10- Cell growth kinetics in both 10% and 2% FBS, with and without 100 nM A939572 was assessed by time-lapse microscopy using an Incucyte Imaging System (Essen Bioscience, Ann Arbor, MI, USA). Photomicrographs were captured every 12 hours. From these photomicrographs, the Incucyte Imaging system calculated the average percent confluence for each treatment and data are reported over a five day period.
Transcription profiling.
H1299 cells were seeded on 6-well plates (25,000 to 30,000 cells/well) in media containing 2% or 10% FBS overnight. Cells were then treated with vehicle (DMSO) or A939572 at the indicated concentration. After 24 hours, cells were lysed with Nucleic Acid Purification Lysis Solution (Applied Biosystems, Foster City, CA, USA) and total RNA was prepared using the Prism 6100 instrument (Applied Biosystems, Foster City, CA, USA). The total RNA was then treated with DNase I in the presence of RNase Inhibitor for 10min, and purified with magnetic beads using BioSprint 96 (Qiagen, Los Angeles, CA, USA). Complementary RNA preparation and hybridization onto U133A arrays was performed according to manufacturer's protocols (Affymetrix, Santa Clara, CA). The hybridization intensity was derived from Affymetrix MAS5.0 algorithm with quantile normalization, obtained from www.bioconductor.org. Probe sets without 2 data points with intensity greater than 100 were removed from further analysis. Significantly changed genes were determined based on a minimum fold change (mean normalized expression value in A939572 treated sample divided by mean normalized expression value in DMSO treated samples) of 1.5 and p-value from t-test of less than 0.005. Taking multiple test correction into consideration, the false discovery rate (FDR) using these criteria is 0.25. Table 2 lists all significantly altered genes with fold changes greater than 2.0.
SCD1 Immunohistochemistry.
A Tissue Microarray (TMA) of formalin fixed, paraffin-embedded tumor tissues was prepared by Asterand UK LTD (Royston, Herts, UK). The TMA contained 11 tissue types including breast, colon, lymphoid and prostate (8 tumor and 2 normal samples of each), gastric, ovary, brain, kidney, liver and skin (4 tumor and 2 normal samples of each), and lung (8 non-small cell tumor and 4 small cell tumor samples, and 4 normal samples). Sections (4μm) of the formalin-fixed, paraffin-embedded (FFPE) TMA were stained using standard immunohistochemistry techniques. Rabbit polyclonal antihuman SCD1 antibody diluted in Background Reducing Diluent (catalog #S3022, DAKO, Carpinteria, CA USA) was applied at a concentration of 1μg/ml. The negative control sections were incubated with a non-immune rabbit IgG antibody (catalog #X0936, DAKO) at 1μg/ml. Antibody amplification and visualization steps were carried out using the CSA II kit (catalog #K1501, DAKO). Following chromagenesis, the sections were counterstained with haematoxylin, dehydrated and coverslipped under DePeX. Stained sections were analyzed, and suitable digital images captured, using an Olympus BX51 microscope with a Leica DFC290 camera attached. IHC analysis of human primary xenograft heterotransplants was performed at Crown Bioscience Inc.
(Santa Clara, CA, USA) following the same protocol.
In vivo pharmacology.
Primary human cancer xenograft studies were performed at Crown Bioscience Inc. The GA16 primary xenograft, derived from a gastric carcinoma patient, was implanted and then maintained subcutaneously in nude mice. GA016 tumors grown to 500-700 mm . Animal body weights were determined on the same days that tumor measurements were taken.
Results

SCD1 depletion by siRNA results in serum-dependent reduction in cell viability.
siRNA knockdown was performed to assess the importance of SCD1 and SCD5 to proliferation and survival of human cancer cells. Cell lines that express both SCD isoforms were transfected with three siRNAs specific for each target and protein levels were determined at 48 hours after transfection ( depleted. However, in cells that were transfected with SCD1 targeting siRNAs cultured in reduced serum conditions (2% FBS), substantial apoptosis induction was observed.
Under these conditions, the relative extent of apoptosis induction between the three SCD1 targeting siRNAs correlated strongly with the degree of SCD1 depletion. In contrast to SCD1, depletion of SCD5 did not result in substantial apoptosis of any cell line tested regardless of serum concentration.
Pharmacologic inhibition of SCD1 results in serum-dependent reduction in cell proliferation.
The results obtained with siRNAs were confirmed using a previously reported inhibitor of SCD1, A939572 (Compound 4C in reference (19) ). The IC 50 value for A939572 was determined using a recombinant microsome desaturation assay that measures formation of tritiated water upon desaturation of stearic acid labeled with tritium at C9 and C10 (17, 20, 21) . The IC 50 value for A939572 was found to be 6.3 nM in human SCD1 expressing microsomes. Additionally, the IC 50 value for A939572 was determined in a cellular assay for desaturation index (DI IC 50 ) ( Fig. 2A) (18) 
Serum derived monounsaturated fatty acids determine expression of SCD1 protein and sensitivity to SCD inhibition.
To explore the mechanism underlying the serum-dependent differential sensitivity of cells to inhibition of SCD, the levels of SCD1 and SCD5 were measured in the sensitive (reduced serum) or resistant (normal serum) contexts. Western blotting for SCD1 and SCD5 in the three cell lines revealed a marked induction of SCD1 in cells cultured in media containing 2% FBS relative to cells cultured in media containing 10% FBS (Fig 3A) . By contrast, SCD5 levels were mostly unchanged by serum concentration. To understand the connection between SCD1 induction in cells grown under reduced or charcoal stripped serum conditions and sensitivity to SCD1 inhibition, cellular IC 50 values for growth inhibition by A939572 were determined (Table 1) . Cells grown in 10% FBS were refractory to growth inhibition by A939572, while cells in reduced serum (2%) or charcoal stripped serum (both 2% and 10%) were highly sensitive to growth inhibition by the SCD1 inhibitor. Differential sensitivity was observed between cells supplemented with 10% or 2% CS-FBS. This likely reflects an incomplete removal of serum lipids by charcoal stripping. Importantly, for all four conditions tested, the relative sensitivity to SCD1 inhibition by A939572 correlated strongly with the relative level of SCD1 induction observed (Figs. 3B and Table 1 ).
To confirm that the sensitization of cells to SCD1 inhibition by reduced serum is related to limiting availability of unsaturated fatty acids, we tested whether cells could be rescued from sensitivity by the addition of exogenous oleic acid conjugated to bovine serum albumin (BSA-conjugated oleic acid) into the growth media (Fig. 3C) 
absence of BSA or BSA-conjugated oleic acid, A939572 treatment caused dosedependent inhibition of cell proliferation. Addition of BSA alone did not alter the dose response of cells to A939572. However, the addition of BSA-conjugated oleic acid showed a dose-dependent rescue of cell sensitivity to A939572 treatment. Levels of SCD1 protein was also examined in cells supplemented with BSA or conjugated oleic acid (Fig. 3D) . The addition of BSA-conjugated oleic acid reduced SCD1 protein levels in a dose-dependent manner relative to supplementation with BSA alone. Extending upon this result, we also tested the effects of supplementing media with other fatty acids, both saturated and unsaturated. Like oleic acid, supplementing growth media with BSAconjugated palmitoleic acid or linoleic acid protected cells from growth inhibition upon SCD1 inhibition while saturated fatty acid supplementation with either stearic acid or palmitic acid did not (supplemental figure S1 ). Further, under these conditions, saturated fatty acid supplementation did not induce cell killing on its own, nor did it enhance the antiproliferative effect of SCD1 inhibition.
Cell killing by SCD1 inhibition in conditions of limiting MUFA occurs via a mechanism involving the ER stress response.
To shed light on the mechanism of cell killing by SCD1 inhibition, H1299 cells were treated with A939572 at 100 nM or DMSO vehicle control under reduced serum conditions and global transcription profiling was performed using Affymetrix microarrays. Analysis of the data revealed 56 statistically significant transcriptional changes (p<0.005 and fold change more than 1.5x), 18 of these changed by more than two-fold. 
paraffin-embedded tissue microarray (TMA) containing 61 cores from 11 common human cancer subtypes was stained using an antibody specific for human SCD1. The staining of representative tissue cores from four tumor types and corresponding normal tissues is shown in Figure 4 . As expected, staining was found predominantly in the perinuclear region of cells staining positive, consistent with the ER localization of SCD1 protein. In many of the tissue cores, variable expression was observed within the tumor ranging from 1+ to 3+ for individual cells ( Figure 4A ). Expression of SCD1 was found to be relatively low in the normal tissues examined compared to the corresponding tumor tissue. This is exemplified by the core pictured in Figure 4B which contained colon cancer tissue as well as adjacent normal colon epithelium. While normal colon epithelial tissue (red box) stained negative for SCD1 protein, colon cancer tissue (green box) showed high levels of SCD1 staining. Certain normal tissues, including breast and prostate, showed moderate SCD1 protein expression in the glandular epithelium (Fig.   4A ). Alveolar macrophages in lung tissue also stained positively for SCD1 expression.
The intensity of staining of each tissue core on the TMA was qualitatively scored using standard pathological scoring terms (0, 1+, 2+, 3+) to assess the overall level of expression of the target protein in the various tissues. SCD1 expression was detectable in greater than 75% of tumors tested (Supplemental Table 1 ). Furthermore, greater than 50% of tumors demonstrated 2+ staining or higher.
Inhibition of SCD1 results in tumor growth inhibition.
Given the potent anti-proliferative activity of A939572 in cultured cells that expressed high levels of SCD1 protein, we set out to evaluate the anti-tumor activity of Figure 5B ). Following 21 days of dosing, the mean tumor volume in the A939572 treated group was reduced by nearly 50% relative to vehicle treated animals. Throughout the study, animal weights were recorded and no significant changes in body weights were observed between A939572 treated and vehicle treated animals ( Figure 5C ). A939572 has been previously reported to cause potent reduction in oleic acid to stearic acid ratios in both liver and plasma samples from mice treated with a single dose of 10 mg/kg (19), ten-fold lower than the dose used in the present study. As SCD1 is the rate limiting enzyme required for the de novo production of monounsaturated fatty acids, we examined whether abundance of serum derived lipids may be responsible for the differential effects of serum content on SCD1 levels and cell sensitivity to SCD1 inhibition. The results presented here provide evidence that SCD1 is induced by cells when exogenous mono or polyunsaturated fatty acids are present in limited quantities and we hypothesize that tumor cells preferentially utilize exogenous unsaturated fatty acids available from the culture media or tumor microenvironment until they become limiting. Once this occurs, SCD1 is induced to enable endogenous biogenesis of unsaturated fatty acids. We also show that supplementation of saturated fatty acids has no effect on the response of cells to SCD1 inhibition further supporting the notion that cells treated with SCD1 inhibitors under conditions of limiting unsaturated fatty acids are growth inhibited due to lack of unsaturated fatty acids rather than buildup of excess saturated fatty acids. Overall, these data provide strong evidence that the availability of exogenous unsaturated fatty acids dictates sensitivity to SCD1 inhibition, and that induction of SCD1 by cells predicts their dependence upon its enzymatic activity. 
under conditions of limiting extracellular unsaturated fatty acids or excessive saturated fatty acids disrupts lipid homeostasis in the ER membrane resulting in ER stress and ultimately apoptotic cell death. Interestingly, ER stress response genes were also found to be differentially regulated in the livers of SCD1 knockout mice fed a very low fat diet when compared to wild-type animals (33). The striking parallel in transcriptional alterations occurring in SCD1 deficient mice fed a very low fat diet and tumor cells exposed to an SCD1 inhibitor under low serum conditions further supports the notion that the availability of exogenous unsaturated lipids is responsible for the differential effects of SCD1 inhibition in varying serum concentrations. Another interesting parallel to the data presented here is that in mice maintained on a very low fat diet, SCD1 mRNA is highly induced (34).
The results presented here strongly suggest that tumor cells require unsaturated fatty acids for survival. In the absence of an exogenous source, tumor cells induce SCD1 expression to allow endogenous lipid desaturation to occur. Under these conditions, SCD1 depletion or pharmacologic inhibition results in cell death via a mechanism involving ER stress. Further, elevated SCD1 protein level strongly predicts sensitivity to SCD1 inhibition. The data presented here demonstrates for the first time that high SCD1 protein expression occurs in a large percentage of human cancers from various tissue origins. Given the prevalence of SCD1 overexpression in human cancers specimens along with the strong correlation between SCD1 expression level and sensitivity to SCD1 inhibition in vitro, it seemed plausible to hypothesize that certain human cancers overexpressing SCD1 might be dependent upon SCD1 for growth and survival. 
Our in vivo antitumor efficacy study demonstrates that tumor growth inhibition can be achieved by pharmacologic inhibition SCD1 without causing any noticeable adverse effects in mice. These data provide strong evidence in support of SCD1 as a potentially viable target for the design of novel anti cancer agents. Since SCD1 expression can be detected in many primary tumors and primary xenografts, additional testing will need to be carried out to thoroughly evaluate the anti-tumor activity of SCD1 inhibitors, and the utility of SCD1 expression as a predictive biomarker for sensitivity to SCD1 inhibition. Tables   Table 1. IC 50 values for inhibition of cell viability by A939572 in FaDu and H1299 cells cultured in 10% or 2% FBS and 10% or 2% charcoal stripped FBS (CS-FBS). 
